ReviewTranslational oncology2025
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.
Review in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Evaluation of Mutation Risk Using Patient-Derived Organoids in Patients With Lynch Syndrome.International journal of cancer · 2026Article
- Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer.Cell reports. Medicine · 2026Article
- Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.Journal of translational medicine · 2026Review
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- Organoid technology in cancer research.Molecular biomedicine · 2026Review
- iPSC-derived cardiac organoids for drug cardiotoxicity evaluation and efficacy prediction in myocardial infarction and cardiac hypertrophy models.Stem cell research & therapy · 2026Article
- Deconstructing cancer in 3D: models, mechanisms, and personalized solutions.Molecular cancer · 2026Review
- Understanding and Overcoming Antibody-Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- New Frontiers of Drug Development Through the Use of New Approach Methodologies.The AAPS journal · 2026Review
- The Role that Biobanks Can Play in Driving Animal-Free Biomedical Research.Expert reviews in molecular medicine · 2026Review
- Ex vivo organotypic culture of liposarcoma effectively models in vivo supratherapeutic paclitaxel localized drug delivery.Translational oncology · 2026Article
- A patient-derived organoid model identifies TP53-dependent gemcitabine sensitivity in spinal chordoma.Discover oncology · 2026Article
- Emerging Frontiers in Ovarian Organoids: Bridging Development,Function, and Disease Modeling: A Review.International journal of fertility & sterility · 2026Article
- Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response.Journal of personalized medicine · 2026Review
- Mitophagy and Ubiquitination Coordinate Context-Specific Mitochondrial Quality Control and EMT/MET Plasticity to Drive Cancer Cell Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The research advances of crosstalk between cancer-associated fibroblasts and tumor cells using co-culture organoids.Cell death & disease · 2026Review
- Patient-derived organoids in functional precision oncology: from experimental models to clinical decision-making.Frontiers in endocrinology · 2026Review
- Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids.Frontiers in bioengineering and biotechnology · 2026Article
- Tumor organoid-immune cell co-culture systems for precision oncology.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived tumor organoids (PDTOs) represent a significant advancement in cancer research and personalized medicine. These organoids, derived from various cancer types, have shown the ability to retain the genetic and molecular characteristics of the original tumors, allowing for the detailed study of tumor biology and drug responses on an individual basis. The success rates of establishing PDTOs vary widely and are influenced by factors such as cancer type, tissue quality, and media composition. Furthermore, the dynamic nature of organoid cultures may also lead to unique molecular characteristics that deviate from the original tumors, affecting their interpretation in clinical settings without the implementation of rigorous validation and establishment of standardized protocols. Recent studies have supported the correlation between PDTOs and the corresponding patient response. Although these studies involved a small number of patients, they promoted the integration of PDTOs in observational and interventional clinical trials to advance translational cancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.